International Journal of Breast Cancer最新文献_第10页

Establishing the Role of Stereotactic Ablative Body Radiotherapy in Early-Stage Breast Cancer. 确定立体定向烧蚀体放疗在早期乳腺癌中的作用。

IF 1.6

International Journal of Breast Cancer Pub Date : 2018-02-01 eCollection Date: 2018-01-01 DOI: 10.1155/2018/2734820

Aisling Barry, Anthony Fyles

引用次数: 0

Rate of Clinical Complete Response for 1 Year or More in Bone-Metastatic Breast Cancer after Comprehensive Treatments including Autologous Formalin-Fixed Tumor Vaccine. 包括自体福尔马林固定肿瘤疫苗在内的骨转移性乳腺癌综合治疗后1年及以上的临床完全缓解率

IF 1.9

International Journal of Breast Cancer Pub Date : 2018-01-22 eCollection Date: 2018-01-01 DOI: 10.1155/2018/4879406

Fumito Kuranishi, Yuki Imaoka, Yuusuke Sumi, Yoji Uemae, Hiroko Yasuda-Kurihara, Takeshi Ishihara, Tsubasa Miyazaki, Tadao Ohno

{"title":"Rate of Clinical Complete Response for 1 Year or More in Bone-Metastatic Breast Cancer after Comprehensive Treatments including Autologous Formalin-Fixed Tumor Vaccine.","authors":"Fumito Kuranishi, Yuki Imaoka, Yuusuke Sumi, Yoji Uemae, Hiroko Yasuda-Kurihara, Takeshi Ishihara, Tsubasa Miyazaki, Tadao Ohno","doi":"10.1155/2018/4879406","DOIUrl":"https://doi.org/10.1155/2018/4879406","url":null,"abstract":"Introduction: No effective treatment has been developed for bone-metastatic breast cancer. We found 3 cases with clinical complete response (cCR) of the bone metastasis and longer overall survival of the retrospectively examined cohort treated comprehensively including autologous formalin-fixed tumor vaccine (AFTV).Patients and methods: AFTV was prepared individually for each patient from their own formalin-fixed and paraffin-embedded breast cancer tissues.Results: Three patients maintained cCR status of the bone metastasis for 17 months or more. Rate of cCR for 1 year or more appeared to be 15% (3/20) after comprehensive treatments including AFTV. The median overall survival time (60.0 months) and the 3- to 8-year survival rates after diagnosis of bone metastasis were greater than those of historical control cohorts in Japan (1988-2002) and in the nationwide population-based cohort study of Denmark (1999-2007).Conclusion: Bone-metastatic breast cancer may be curable after comprehensive treatments including AFTV, although larger scale clinical trial is required.","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"2018 ","pages":"4879406"},"PeriodicalIF":1.9,"publicationDate":"2018-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2018/4879406","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35945968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

The Use of Sentinel Lymph Node Biopsy in BRCA1/2 Mutation Carriers Undergoing Prophylactic Mastectomy: A Retrospective Consecutive Case-Series Study. 在接受预防性乳房切除术的 BRCA1/2 基因突变携带者中使用前哨淋巴结活检：回顾性连续病例系列研究。

IF 1.9

International Journal of Breast Cancer Pub Date : 2018-01-01 DOI: 10.1155/2018/1426369

Sara Câmara, Daniela Pereira, Saudade André, Beatriz Mira, Fátima Vaz, Rodrigo Oom, José Carlos Marques, João Leal de Faria, Catarina Rodrigues Dos Santos

{"title":"The Use of Sentinel Lymph Node Biopsy in BRCA1/2 Mutation Carriers Undergoing Prophylactic Mastectomy: A Retrospective Consecutive Case-Series Study.","authors":"Sara Câmara, Daniela Pereira, Saudade André, Beatriz Mira, Fátima Vaz, Rodrigo Oom, José Carlos Marques, João Leal de Faria, Catarina Rodrigues Dos Santos","doi":"10.1155/2018/1426369","DOIUrl":"10.1155/2018/1426369","url":null,"abstract":"Introduction: Sentinel lymph node biopsy in prophylactic mastectomy is controversial. It avoids lymphadenectomy in occult carcinoma but is associated with increased morbidity. Women with BRCA mutations have a higher incidence of occult carcinoma and our objective was to assess the clinical utility of sentinel lymph node biopsy when these women undergo prophylactic mastectomy.Materials and methods: Seven-year retrospective consecutive case-series study of women, with a BRCA deleterious mutation, admitted to prophylactic mastectomy, at our center. Breast MRI < 6 months before surgery was routine, unless contraindicated.Results: Fifty-seven patients (43% BRCA1; 57% BRCA2) underwent 80 prophylactic mastectomies. 72% of patients had had breast cancer treated before prophylactic mastectomy or synchronously to it. The occult carcinoma incidence was 5%, and half of the cases were invasive. SLNB was performed in 19% of the prophylactic mastectomies; none of these had tumor invasion. Women with invasive carcinoma who had not undergone sentinel lymph node biopsy were followed closely with axillary ultrasound. The median follow-up was 37 months, with no local recurrence; 1 patient died of primary tumor systemic relapse.Conclusions: Our data do not support this procedure for routine (in agreement with previous literature), in this high risk for occult carcinoma population.","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"2018 ","pages":"1426369"},"PeriodicalIF":1.9,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817815/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35885507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Semaphorin 3A Increases FAK Phosphorylation at Focal Adhesions to Modulate MDA-MB-231 Cell Migration and Spreading on Different Substratum Concentrations 信号蛋白3A增加FAK在局灶黏附中的磷酸化，调节MDA-MB-231细胞在不同基质浓度下的迁移和扩散

IF 1.9

International Journal of Breast Cancer Pub Date : 2017-01-15 DOI: 10.1155/2017/9619734

Scott Gehler, Frances V. Compere, A. M. Miller

{"title":"Semaphorin 3A Increases FAK Phosphorylation at Focal Adhesions to Modulate MDA-MB-231 Cell Migration and Spreading on Different Substratum Concentrations","authors":"Scott Gehler, Frances V. Compere, A. M. Miller","doi":"10.1155/2017/9619734","DOIUrl":"https://doi.org/10.1155/2017/9619734","url":null,"abstract":"Interactions between integrin-mediated adhesions and the extracellular matrix (ECM) are important regulators of cell migration and spreading. However, mechanisms by which extracellular ligands regulate cell migration and spreading in response to changes in substratum concentration are not well understood. Semaphorin 3A (Sema3A) has been shown to inhibit cell motility and alter integrin signaling in various cell types. We propose that Sema3A alters focal adhesions to modulate breast carcinoma cell migration and spreading on substrata coated with different concentrations of ECM. We demonstrate that Sema3A inhibits MDA-MB-231 cell migration and spreading on substrata coated with high concentrations of collagen and fibronectin but enhances migration and spreading at lower concentrations of collagen and fibronectin. Sema3A increases focal adhesion kinase phosphorylation at tyrosine 397 (pFAK397) at focal adhesions on all substratum concentrations of collagen and fibronectin but decreased pFAK397 levels on laminin. Rho-associated protein kinase (ROCK) inhibition blocks the Sema3A-mediated effects on cell migration, spreading, and pFAK397 at focal adhesions when cultured on all concentrations of collagen. These results suggest that Sema3A shifts the optimal level of cell-matrix adhesions to a nonoptimal ECM coating concentration, in particular collagen, to yield maximal cell migration and spreading that may be mediated through a ROCK-dependent mechanism.","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"81 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2017-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89663012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 16

Correlation of Oncotype DX Recurrence Score with Histomorphology and Immunohistochemistry in over 500 Patients 500多例Oncotype DX复发评分与组织形态学和免疫组织化学的相关性

IF 1.9

International Journal of Breast Cancer Pub Date : 2017-01-12 DOI: 10.1155/2017/1257078

M. Hanna, I. Bleiweiss, A. Nayak, S. Jaffer

{"title":"Correlation of Oncotype DX Recurrence Score with Histomorphology and Immunohistochemistry in over 500 Patients","authors":"M. Hanna, I. Bleiweiss, A. Nayak, S. Jaffer","doi":"10.1155/2017/1257078","DOIUrl":"https://doi.org/10.1155/2017/1257078","url":null,"abstract":"Oncotype Dx is used to determine the recurrence risk (RR) in patients with estrogen receptor positive (ER+) and lymph node negative (LN−) breast cancer. The RR is divided into low (0–17), intermediate (18–30), and high (31) to predict chemotherapy benefit. Our goal was to determine the association between histomorphology, immunohistochemistry, and RR. We retrospectively identified 536 patients with ER+ and LN− breast cancers that underwent Oncotype testing from 2006 to 2013. Tumor size ranged from 0.2 cm to 6.5 cm (mean = 1.3 cm) and was uniform in all 3 categories. The carcinomas were as follows: ductal = 63.2%, lobular = 11.1%, and mixed = 35.7%. The RR correlated with the Nottingham grade. Increasing RR was inversely related to PR positivity but directly to Her2 positivity. Of the morphologic parameters, a tubular(lobular) morphology correlated only with low-intermediate scores and anaplastic type with intermediate-high scores. Other morphologies like micropapillary and mucinous were uniformly distributed in each category. Carcinomas with comedo intraductal carcinoma were more likely associated with high RR. Forty-four patients with either isolated tumor cells or micrometastases were evenly distributed amongst the 3 RR. While there was only 1 ER discrepancy between our immunohistochemistry (3+ 80%) and Oncotype, up to 8% of PR+ cases (mean = 15%, median = 5%) and 2% of HER2+ cases were undervalued by Oncotype.","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"43 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2017-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75770205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 36

Quality of Breast Cancer Information on the Internet by African Organizations: An Appraisal 非洲组织在互联网上的乳腺癌信息质量:评估

IF 1.9

International Journal of Breast Cancer Pub Date : 2017-01-11 DOI: 10.1155/2017/2026979

C. P. Akuoko

{"title":"Quality of Breast Cancer Information on the Internet by African Organizations: An Appraisal","authors":"C. P. Akuoko","doi":"10.1155/2017/2026979","DOIUrl":"https://doi.org/10.1155/2017/2026979","url":null,"abstract":"Objective. The aim of this study was to appraise the quality of information on BC available at websites run by organizations in Africa. Methods. Three searches were conducted using Google search engine to generate a list of websites. The identified websites were assessed using European Commission (EC) quality criteria for health-related websites, which comprises different assessment areas including, completeness, transparency and honesty, authority, privacy and data protection, updating of information, accountability, and accessibility. Results. Thirteen (13) websites were included in the evaluation. Majority of the websites evaluated had low scores on the completeness and transparency of their websites. Scores on accessibility were however moderate and high for most of the websites. Breast cancer-specific organizations provided the highest quality information, particularly in terms of completeness. The overall lowest and highest quality scores were 9 and 43 out of 63, respectively, and 77% of the included websites scored less than 50% of the total quality score. Conclusion. This review has provided evidence of inadequate and inaccurate BC information provided by some cancer organizations in Africa. Considerable effort is required to make BC information on the Internet a valuable and up-to-date source for both professionals and patients.","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"58 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2017-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85521170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Obesity and Prognostic Variables in Colombian Breast Cancer Patients: A Cross-Sectional Study. 哥伦比亚乳腺癌患者的肥胖和预后变量:一项横断面研究

IF 1.9

International Journal of Breast Cancer Pub Date : 2017-01-01 Epub Date: 2017-05-18 DOI: 10.1155/2017/9574874

Javier Cuello-López, Ana Fidalgo-Zapata, Elsa Vásquez-Trespalacios

{"title":"Obesity and Prognostic Variables in Colombian Breast Cancer Patients: A Cross-Sectional Study.","authors":"Javier Cuello-López, Ana Fidalgo-Zapata, Elsa Vásquez-Trespalacios","doi":"10.1155/2017/9574874","DOIUrl":"https://doi.org/10.1155/2017/9574874","url":null,"abstract":"Introduction: Obesity is an established risk factor for cancer and cancer-related deaths, including that of the breast. While the prevalence of female obesity has accelerated over the past decade in many developing countries, such as Colombia, the prevalence of overweight and obesity specifically in breast cancer populations has not been fully described.Methods: A cross-sectional study including 849 women diagnosed with breast cancer between 2009 and 2014. Based on body mass index, prevalence of overweight (BMI ≥ 25 < 30) and obesity (BMI ≥ 30) and associations of BMI with clinical and tumor histopathological features were analyzed.Results: Colombian breast cancer patients had a prevalence of overweight of 34.28% and obesity of 28.15%. Mean BMI was comparable between premenopausal and postmenopausal women (27.2 versus 27.7, resp.). Among premenopausal women, higher BMI was significantly positively associated with hormone receptor negative tumors, as well as with greater lymphovascular invasion.Conclusions: Colombian breast cancer patients exhibit a significant prevalence of overweight and obesity. Associations of high BMI and poor prognosis variables in the premenopausal population suggest risk of aggressive disease in this population. Future studies to further validate our observations are warranted in order to implement multidisciplinary clinical guidelines.","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"2017 ","pages":"9574874"},"PeriodicalIF":1.9,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2017/9574874","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35084093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

A Nationwide Survey of UK Oncologists' Views on the Choice of Radiotherapy Regime for the Reconstructed Chest Wall in Breast Cancer Patients 英国肿瘤学家对乳腺癌患者重建胸壁放疗方案选择看法的全国调查

IF 1.9

International Journal of Breast Cancer Pub Date : 2017-01-01 DOI: 10.1155/2017/6385432

N. Davis, R. Jyothirmayi

{"title":"A Nationwide Survey of UK Oncologists' Views on the Choice of Radiotherapy Regime for the Reconstructed Chest Wall in Breast Cancer Patients","authors":"N. Davis, R. Jyothirmayi","doi":"10.1155/2017/6385432","DOIUrl":"https://doi.org/10.1155/2017/6385432","url":null,"abstract":"Aims. This paper describes a UK survey of the choice of radiotherapy regime for the reconstructed chest wall in breast cancer patients. Questions focused on which fractionation regime consultants choose, their reasons for this, whether the type of reconstruction influences their choice, and whether bolus is used in patients who have undergone immediate reconstructive surgery. Materials and Methods. Between July 2014 and July 2015 a survey was sent by email to UK consultant radiation oncologists treating breast cancer. Results. The response rate was 73%. 67% of respondents use 40 Gray (Gy) in 15 fractions, with 22% using 50 Gy in 25 fractions and 7% using other regimes. For 90% of consultants the type of reconstruction did not influence their decision regarding choice of fractionation. 83% of respondents do not usually use a bolus for chest wall radiotherapy in patients who have had immediate reconstructive surgery. Conclusions. This survey illustrates there is variation in practice in the management of patients with breast cancer who have undergone immediate reconstructive surgery in the UK. There is a need for further research to determine which fractionation regime is optimal, whether the type of surgery is relevant, and whether bolus should be added.","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"93 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82719787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

P-Rex1 Expression in Invasive Breast Cancer in relation to Receptor Status and Distant Metastatic Site. P-Rex1在浸润性乳腺癌中的表达与受体状态和远处转移部位的关系

IF 1.9

International Journal of Breast Cancer Pub Date : 2017-01-01 Epub Date: 2017-06-15 DOI: 10.1155/2017/4537532

Jonathan D Marotti, Kristen E Muller, Laura J Tafe, Eugene Demidenko, Todd W Miller

{"title":"P-Rex1 Expression in Invasive Breast Cancer in relation to Receptor Status and Distant Metastatic Site.","authors":"Jonathan D Marotti, Kristen E Muller, Laura J Tafe, Eugene Demidenko, Todd W Miller","doi":"10.1155/2017/4537532","DOIUrl":"https://doi.org/10.1155/2017/4537532","url":null,"abstract":"Background: Phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 1 (P-Rex1) has been implicated in cancer growth, metastasis, and response to phosphatidylinositol 3-kinase (PI3K) inhibitor therapy. The aim of this study was to determine whether P-Rex1 expression differs between primary and metastatic human breast tumors and between breast cancer subtypes.Design: P-Rex1 expression was measured in 133 specimens by immunohistochemistry: 40 and 42 primary breast tumors from patients who did versus did not develop metastasis, respectively, and 51 breast-derived tumors from metastatic sites (36 of which had matching primary tumors available for analysis).Results: Primary breast tumors showed significant differences in P-Rex1 expression based on receptor subtype. ER+ and HER2+ primary tumors showed higher P-Rex1 expression than primary triple-negative tumors. HER2+ metastases from all sites showed significantly higher P-Rex1 expression compared to other metastatic receptor subtypes. Solid organ (i.e., brain, lung, and liver) metastases showed higher P-Rex1 expression compared to bone metastases.Conclusions: P-Rex1 expression is increased in ER+ and HER2+ breast cancers compared to triple-negative tumors. P-Rex1 may be differentially expressed in metastatic tumors based on site and receptor status. The role of P-Rex1 in the development of breast cancer metastases and as a predictive biomarker of therapeutic response warrants further investigation.","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"2017 ","pages":"4537532"},"PeriodicalIF":1.9,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2017/4537532","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35160801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 11

Molecular Signatures of Radiation Response in Breast Cancer: Towards Personalized Decision-Making in Radiation Treatment. 乳腺癌放射反应的分子特征:面向放射治疗的个性化决策。

IF 1.9

International Journal of Breast Cancer Pub Date : 2017-01-01 Epub Date: 2017-11-26 DOI: 10.1155/2017/4279724

Corey Speers, Lori J Pierce

引用次数: 20